BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 12082525)

  • 1. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
    Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
    Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1.
    Rae FK; Martinez G; Gillinder KR; Smith A; Shooter G; Forrest AR; Grimmond SM; Little MH
    Oncogene; 2004 Apr; 23(17):3067-79. PubMed ID: 15021918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of WT1 target gene expression in stably transfected cell lines.
    Thäte C; Englert C; Gessler M
    Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1).
    Dehbi M; Ghahremani M; Lechner M; Dressler G; Pelletier J
    Oncogene; 1996 Aug; 13(3):447-53. PubMed ID: 8760285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
    Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the WT1 tumor suppressor gene promoter by Pea3.
    Discenza MT; Vaz D; Hassell JA; Pelletier J
    FEBS Lett; 2004 Feb; 560(1-3):183-91. PubMed ID: 14988020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
    Morrison DJ; English MA; Licht JD
    Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2.
    McConnell MJ; Cunliffe HE; Chua LJ; Ward TA; Eccles MR
    Oncogene; 1997 Jun; 14(22):2689-700. PubMed ID: 9178767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
    Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
    Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
    Han Y; San-Marina S; Yang L; Khoury H; Minden MD
    Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
    Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
    Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
    Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
    Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling.
    Kennedy D; Ramsdale T; Mattick J; Little M
    Nat Genet; 1996 Mar; 12(3):329-31. PubMed ID: 8589729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.